GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology

GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa